文献速递糖尿病

利拉鲁肽对心血管高危2型糖尿病患者糖尿病足溃疡及其并发症的影响:LEADER试验结果

The Impact of Liraglutide on Diabetes-Related Foot Ulceration and Associated Complications in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events: Results From the LEADER Trial.
PubMed 文献 · Diabetes Care · 2018-08-02

LEADER试验事后分析评估利拉鲁肽(1.8 mg/日)与安慰剂对心血管高危2型糖尿病患者糖尿病足溃疡(DFU)及其后遗症的影响。中位随访3.8年,两组DFU发生率相似(利拉鲁肽组3.8% vs 安慰剂组4.1%;HR 0.92,95%CI 0.75-1.13;P=0.41),但利拉鲁肽组DFU相关截肢风险显著降低(HR 0.65,95%CI 0.45-0.95;P=0.03)。足部感染、深层结构受累或外周血运重建方面无差异。

要点

  • 利拉鲁肽不增加心血管高危2型糖尿病患者的DFU风险。
  • 利拉鲁肽组DFU相关截肢风险显著低于安慰剂组(HR 0.65)。
  • 足部感染、深层结构受累及外周血运重建两组无差异。

核心结论

  • 在心血管高危2型糖尿病患者中,利拉鲁肽治疗未增加DFU事件风险,且与DFU相关截肢风险显著降低相关。
  • 该关联可能源于偶然,需进一步研究。

研究设计与样本

  • LEADER试验(NCT01179048)为随机、双盲、多中心心血管结局试验。
  • 受试者为心血管高危2型糖尿病患者,比较利拉鲁肽1.8 mg/日与安慰剂(均在标准治疗基础上),最长5年。
  • DFU信息在试验期间系统收集,DFU并发症通过事后审阅病例叙述评估。

主要发现

  • 中位随访3.8年,利拉鲁肽组至少一次DFU报告比例为3.8%(176/4,668),安慰剂组为4.1%(191/4,672)(HR 0.92,95%CI 0.75-1.13;P=0.41)。
  • 利拉鲁肽组DFU相关截肢风险显著低于安慰剂组(HR 0.65,95%CI 0.45-0.95;P=0.03)。
  • 主分析中,足部感染、深层结构受累及外周血运重建两组无差异。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Diabetes-related foot ulcers (DFUs) and their sequelae result in large patient and societal burdens. Long-term data determining the efficacy of individual glucose-lowering agents on DFUs are lacking. Using existing data from the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial, we conducted post hoc analyses assessing the impact of liraglutide versus placebo in people with type 2 diabetes and at high risk of cardiovascular (CV) events on the incidence of DFUs and their sequelae. RESEARCH DESIGN AND METHODS: The LEADER trial (NCT01179048) was a randomized, double-blind, multicenter, CV outcomes trial assessing liraglutide (1.8 mg/day) versus placebo, in addition to standard of care, for up to 5 years. Information on DFUs was collected systematically during the trial, and DFU complications were assessed post hoc through reviewing case narratives. RESULTS: During a median of 3.8 years' follow-up, similar proportions of patients reported at least one episode of DFU in the liraglutide and placebo groups (3.8% [176/4,668] versus 4.1% [191/4,672], respectively; hazard ratio [HR] 0.92 [95% CI 0.75, 1.13; P = 0.41]). Analysis of DFU-related complications demonstrated a significant reduction in amputations with liraglutide versus placebo (HR 0.65 [95% CI 0.45, 0.95; P = 0.03]). However, no differences were found for foot infections, involvement of underlying structures, or peripheral revascularization in the main analysis. CONCLUSIONS: Treatment with liraglutide in patients with type 2 diabetes and at high risk of CV events in the LEADER trial did not increase the risk of DFU events and was associated with a significantly lower risk of DFU-related amputations compared with placebo. This association, possibly due to chance, needs further investigation.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Dhatariya K, Bain SC, Buse JB, et al. The Impact of Liraglutide on Diabetes-Related Foot Ulceration and Associated Complications in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events: Results From the LEADER Trial. Diabetes Care. 2018. PMID: 30072400. doi:10.2337/dc18-1094

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。